A Clinico Comparative study on the role of virechana karma and Vamana karma in the management of amavata.
Not Applicable
- Conditions
- Health Condition 1: M069- Rheumatoid arthritis, unspecified
- Registration Number
- CTRI/2023/08/056946
- Lead Sponsor
- SV Ayurvedic College and Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Patients aged between 18 to 60 years and all genders.
2.Patients presenting with the signs and symptoms of Amav ?ta.
3.Patients presenting with 2010 ACR Criteria for Rheumatoid arthritis.
4.Patients who are eligible for Vamana karma.
5.Patients who are eligible for Virechana karma.
Exclusion Criteria
1.Patients below the age of 18 and above the age of 60 years.
2.Patients with Diabetes and Hypertension.
3.Patients with Rheumatoid Arthritis (Amav ?ta) associated with other arthritic conditions such as Gouty arthritis, Osteo arthritis etc.,
4.Patients associated with any other major systemic illness such as malignancies, T.B, HIV etc.,
5.Dyslipidemia.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.To evaluate the efficacy of Vamana (K?tavedan ? siddha yoga) followed by Virechana (E?anda Haritaki yoga) in the management of Amav ?ta in terms of Interleukin 6 (IL-6). <br/ ><br>2.To evaluate the efficacy of Virechana (E?anda Haritaki yoga) in the management of Amav ?ta in terms of Interleukin 6 (IL-6). <br/ ><br> <br/ ><br>Timepoint: At baseline after completion of treatment (21th - 39th days) <br/ ><br>
- Secondary Outcome Measures
Name Time Method To evaluate the efficacy of Vamana (K?tavedan ? siddha yoga) followed by Virechana (E?anda Haritaki yoga) in the management of Amav ?ta in terms of Interleukin 6 (IL-6). <br/ ><br>To evaluate the efficacy of Virechana (E?anda Haritaki yoga) in the management of Amav ?ta in terms of Interleukin 6 (IL-6). <br/ ><br>Timepoint: At baseline, after completion of treatment(21th-39th days)